BioCryst Pharmaceuticals
BCRX
BCRX
103 hedge funds and large institutions have $501M invested in BioCryst Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 25 increasing their positions, 36 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
0% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 10
1.81% less ownership
Funds ownership: 90.34% → 88.53% (-1.8%)
31% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 36
Holders
103
Holding in Top 10
2
Calls
$972K
Puts
$484K
Top Buyers
| 1 | +$19.7M | |
| 2 | +$3.84M | |
| 3 | +$1.61M | |
| 4 |
VMI
VHCP Management II
New York
|
+$1.39M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$721K |
Top Sellers
| 1 | -$7.47M | |
| 2 | -$5.7M | |
| 3 | -$4.74M | |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$3.87M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.26M |